108 Results for "

Hgf

" in MedChemExpress (MCE) Product Catalog:
Products (108)

108 Results for "Hgf" in MCE Product Catalog:

  • Categories Recommended:
    More
1
1 Cited Publications
Cat. No.: HY-P700216AF
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL6; Hybridoma Growth Factor; Prev. IFNB2; IFN-Beta-2; IL-6; BSF-2; Interleukin-6; CDF; BSF2; Interleukin 6 (Interferon, Beta 2); Hgf; B-Cell Differentiation Factor; HSF; Truncated Interleukin 6; B-Cell Stimulatory Factor 2; Interferon, Beta 2; CTL Differ
Species:  
Mouse
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-P99391
CAS No.: 1781223-80-0
Synonyms: ABT-700; ABBV-400 Antibody

Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
loading...
    loading...
Cat. No.: HY-P99192
CAS No.: 1365287-97-3
Synonyms: LY2875358

Target:  

c-Met/HGFR

Research Areas:  

Cancer

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
loading...
    loading...
Cat. No.: HY-137455
CAS No.: 1070881-42-3
Purity:  99.89%
Synonyms: ANG-3777
Target:  

c-Met/HGFR

Research Areas:  

Inflammation/Immunology

Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor .
loading...
    loading...
Cat. No.: HY-P99217
CAS No.: 872514-65-3
Synonyms: AMG 102

Target:  

c-Met/HGFR

Research Areas:  

Cancer

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
loading...
    loading...
Cat. No.: HY-P99196
CAS No.: 1174900-84-5

Target:  

c-Met/HGFR

Research Areas:  

Cancer

Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
loading...
    loading...
Cat. No.: HY-106961
CAS No.: 176391-41-6
Purity:  99.06%
Synonyms: ONO-AP 500-02
Research Areas:  

Cardiovascular Disease

ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
loading...
    loading...
Cat. No.: HY-106961A
CAS No.: 153814-74-5
Synonyms: (Z)-ONO-AP 500-02
Research Areas:  

Cardiovascular Disease

(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
loading...
    loading...
Cat. No.: HY-176901
CAS No.: 874744-59-9
Target:  

c-Met/HGFR

Research Areas:  

Cancer

HGF-IN-1 ((the compound on the left in the second line of page 77) is a HGF inhibitor. HGF-IN-1 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-114363
CAS No.: 1832686-43-7
Target:  

c-Met/HGFR

Research Areas:  

Cancer

SRI 31215 is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P991660

Target:  

c-Met/HGFR

Research Areas:  

Cancer

ARGX-111 is an anti-MET antibody. ARGX-111 blocks HGF-dependent and -independent signaling, downregulating MET expression on the tumor cell surface. ARGX-111 depletes MET-expressing circulating tumor cells through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thereby inhibiting tumor metastasis. ARGX-111 depletes circulating tumor cells and inhibits bone and lung metastasis in an orthotopic mouse model of metastatic breast cancer. ARGX-111 is promising for research in breast cancer and other cancers .
loading...
    loading...
Cat. No.: HY-P991589
Synonyms: NOV-1105

Target:  

c-Met/HGFR

Research Areas:  

Cancer

SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
loading...
    loading...
Cat. No.: HY-P1415
CAS No.: 334994-34-2
Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .
loading...
    loading...
Cat. No.: HY-P991565

Target:  

c-Met/HGFR

Research Areas:  

Cancer

CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
loading...
    loading...
Cat. No.: HY-P99391A
CAS No.: 1781223-80-0
Synonyms: ABT-700 (powder)

Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
loading...
    loading...
Cat. No.: HY-10338A
CAS No.: 1226999-07-0
Target:  

c-Met/HGFR VEGFR

Research Areas:  

Cancer

Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .
loading...
    loading...
Cat. No.: HY-165284
CAS No.: 1370652-56-4
Research Areas:  

Cancer

CM-118 is a potent and selective c-Met and ALK inhibitor. CM-118 inhibits the HGF-induced c-Met phosphorylation. CM-118 inhibits phosphorylation of ALK, EML4-ALKv1, ALK F1174L, and EMl4-ALKv1 L1196M, with respective IC50 values 0.92, 1.25, 1.9, and 3.5 μM. CM-118 exhibits anticancer activity against cancers dependent on the c-Met or ALK oncogenic pathways .
loading...
    loading...
Cat. No.: HY-E70751
Target:  

c-Met/HGFR

Research Areas:  

Cancer

Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET G1163R is a mutant of MET. MET G1163R Recombinant Human Active Protein Kinase is a recombinant MET G1163R protein that can be used to study MET G1163R-related functions .
loading...
    loading...
Cat. No.: HY-E70758
Target:  

c-Met/HGFR

Research Areas:  

Cancer

Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1235D is a mutant of MET. MET Y1235D Recombinant Human Active Protein Kinase is a recombinant MET Y1235D protein that can be used to study MET Y1235D-related functions .
loading...
    loading...
Cat. No.: HY-174670
Target:  

mRNA

Research Areas:  

Cancer

Human HGF mRNA encodes the human hepatocyte growth factor (HGF) protein, a protein that binds to the hepatocyte growth factor receptor to regulate cell growth, cell motility and morphogenesis in numerous cell and tissue types. It also plays a role in angiogenesis, tumorogenesis, and tissue regeneration.
loading...
    loading...